Gilead Sciences News - June 2026
🟢 GILD is trading 3.1% up today after FDA approves Trodelvy for first-line breast cancer treatment
GILD is trading 3.1% up at $127.69 after the FDA approved its cancer drug Trodelvy for the first-line treatment of metastatic triple-negative breast cancer. •...
Gilead’s Trodelvy Wins FDA Approval for First-Line Breast Cancer, Expanding Market
Gilead Sciences received FDA approval for Trodelvy as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). This approval transitions...
🟢 Gilead Sciences Inc is trading 2.02% up today after FDA accepts its once-weekly HIV PrEP filing for Yeztugo
Gilead Sciences Inc is trading at $126.81 (+2.02%) today after the FDA accepted its supplemental New Drug Application (sNDA) for Yeztugo (lenacapavir) as a...